EDAP TMS

EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses on the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

EDAP TMS reports Q1 revenue growth and FDA breakthrough designation

EDAP TMS reported solid revenue growth in Q1 2024, driven by strong international placements and advancements in Focal One technology. While facing financial challenges, the company is strategically positioned to benefit from the expanding HIFU market and upcoming regulatory milestones. Opportunities lie in market expansion, new study data releases, and continued engagement with regulatory bodies.

EDAP TMS reports strong Q2 earnings, poised for market expansion

EDAP TMS delivered robust performance in Q2 2024, driven by revenue growth and advancements in key medical programs.
While facing challenges in profitability and expenses, the company is strategically positioned to capitalize on market opportunities.
Investments in research, management, and clinical trials signal a proactive approach towards sustainable growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Company to host conference call and webcast on Thursday , August 25 th at 8:30 am EDT

EDAP TMS SA to Announce Second Quarter 2022 Financial Results on August 24th, 2022

EDAP TMS S.A. (EDAP) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks.

Here's Why "Trend" Investors Would Love Betting on EDAP TMS S.A. (EDAP)

EDAP TMS S.A. (EDAP) witnessed a jump in share price last session on above-average trading volume.

Strength Seen in EDAP TMS S.A. (EDAP): Can Its 13.4% Jump Turn into More Strength?

Proposed rule, if adopted for CY23 , would increase Medicare Payment for a Focal One HIFU procedure completed on an outpatient basis at a hospital

EDAP Announces Focal One® HIFU Reimbursement Raised to Urology APC Level 6 Under CMS Outpatient Prospective Payment System (OPPS) Proposed Rule for CY23

Here is how EDAP TMS S.A. (EDAP) and Fstar Therapeutics, Inc. (FSTX) have performed compared to their sector so far this year.

Has EDAP TMS (EDAP) Outpaced Other Medical Stocks This Year?

LYON, France, June 28, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced its participation to two major forthcoming international robotics and urology congresses

EDAP's Focal One® HIFU to be Showcased at Two Major Robotics & Urology International Congresses

LYON, France, June 6, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that three oral presentations will be delivered on its HIFU developments at the 21st Annual International Symposium on Therapeutic Ultrasound (ISTU), which is being held June 7-10, in Toronto and virtually.

EDAP Announces Multiple Oral Presentations at the 21st International Symposium on Therapeutic Ultrasound

EDAP TMS S.A. (NASDAQ:EDAP ) Q1 2022 Earnings Conference Call May 18, 2022 8:30 AM ET Company Participants John Fraunces - LifeSci Advisors, Investor Relations Marc Oczachowski - Chief Executive Officer and Chairman of the Board of Directors Ryan Rhodes - Chief Executive Officer, EDAP US Francois Dietsch - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Operator Greetings.

EDAP TMS S.A. (EDAP) CEO Marc Oczachowski on Q1 2022 Results - Earnings Call Transcript

LYON, France, May 17, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced today unaudited financial results for the first quarter 2022.

EDAP Reports First Quarter 2022 Results

Company to host conference call and webcast on , Wednesday, May 18 th at 8:30 am EDT

EDAP TMS SA to Announce First Quarter 2022 Financial Results on May 17, 2022

LYON, France, May 5, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the company will be showcasing and exhibiting its Focal One® Robotic High Intensity Focused Ultrasound (HIFU) platform at the upcoming Annual Meeting of the American Urological Association (AUA), the largest gathering of urologists worldwide, which will be held May 13th through 15th in New Orleans.

EDAP to Showcase its Focal One® Platform at the Annual Meeting of the American Urological Association (AUA)

Company announces Focal One® placements at three renowned academic institutions in March

EDAP Provides Corporate Update on US Focal One® Installation Growth

EDAP TMS S.A. (EDAP) CEO Marc Oczachowski on Q4 2021 Results - Earnings Call Transcript

LYON, France, March 30, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced today unaudited financial results for the fourth quarter and full year 2021.

EDAP Reports Fourth Quarter and Full Year 2021 Results

Company to host conference call and webcast on Thursday, March 31 , at 8:30 am ET

EDAP TMS SA to Announce Fourth Quarter 2021 Financial Results on Wednesday, March 30, 2022

LYON, France, February 1, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today issued the following letter to shareholders:

EDAP Issues Letter to Shareholders

After a somewhat disappointing Q3 and a disappointing reimbursement decision, things definitely picked up in Q4.

Acceleration At EDAP

Company announces s everal k ey U.S. Focal One installations during Q4

EDAP Provides Corporate Update on US Focal One Installation Growth

LYON, France, November 29, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the company will participate in a fireside chat and host investor 1x1 meetings at the Piper Sandler 33rd Annual Virtual Healthcare Conference, which is being held November 29 - December 2.

EDAP to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

EDAP TMS S.A. (EDAP) CEO Marc Oczachowski on Q3 2021 Results - Earnings Call Transcript

LYON, France, November 17, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced today unaudited financial results for the third quarter of 2021 and provided an update on strategic and operational developments.

EDAP Reports Third Quarter 2021 Results and Provides Operational Update

Company to host conference call and webcast on Thursday, November 18, at 8:30 am ET

EDAP TMS SA to Announce Third Quarter 2021 Financial Results on Wednesday, November 17, 2021

Brings advanced focal ablation to prostate cancer patients in the Pacific Northwest

EDAP Announces University of Washington Medicine to Launch Focal One® Robotic HIFU Program

LYON, France, September 7, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), a global leader in robotic energy-based therapies, today announced that management will present at the following investor conferences during the month of September 2021:

EDAP to Participate at Upcoming Investor Conferences

Favorable changes in market acceptance and reimbursement for the FocalOne have been obscured by pandemic headwinds.

News for EDAP TMS Stock (EDAP)